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ttps://doi.org/10.1016/j.ajpath.2019.05.018Inﬂammatory bowel disease is characterized by high levels of inﬂammation and loss of barrier integrity
in the colon. The intestinal barrier is a dynamic network of proteins that encircle intestinal epithelial
cells. miRNAs regulate protein-coding genes. In this study, miR-24 was found to be elevated in colonic
biopsies and blood samples from ulcerative colitis (UC) patients compared with healthy controls. In the
colon of UC patients, miR-24 is localized to intestinal epithelial cells, which prompted an investigation
of intestinal epithelial barrier function. Two intestinal epithelial cell lines were used to study the effect
of miR-24 overexpression on barrier integrity. Overexpression of miR-24 in both cell lines led to
diminished transepithelial electrical resistance and increased dextran ﬂux, suggesting an effect on
barrier integrity. Overexpression of miR-24 did not induce apoptosis or affect cell proliferation, sug-
gesting that the effect of miR-24 on barrier function was due to an effect on cellecell junctions.
Although the tight junctions in cells overexpressing miR-24 appeared normal, miR-24 overexpression
led to a decrease in the tight junctioneassociated protein cingulin. Loss of cingulin compromised
barrier formation; cingulin levels negatively correlated with disease severity in UC patients. Together,
these data suggest that miR-24 is a signiﬁcant regulator of intestinal barrier that may be important in
the pathogenesis of UC. (Am J Pathol 2019, 189: 1763e1774; https://doi.org/10.1016/
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Trent University, Nottingham, UK.Inﬂammatory bowel disease (IBD) is comprised broadly of
two subcategories: Crohn disease (CD) and ulcerative colitis
(UC). CD and UC are chronic inﬂammatory diseases of the
gastrointestinal tract, currently affecting >1.6 million
Americans.1 With a complex etiology and limited lasting
medical treatments, IBD patients may experience a lifetime
of signiﬁcant symptoms, which include severe diarrhea,
bleeding, and vomiting. One pathophysiological feature of
IBD patients is a loss of the intestinal barrier, even in areas
that contain an intact epithelium.2,3 The intestinal barrier
comprises a single layer of epithelial cells bound together by
proteins that traverse the plasma membrane. This selectively
permeable barrier compartmentalizes bacteria and other
toxins to the lumen while allowing ions, nutrients, and water
to be absorbed. Loss of the intestinal barrier leads to the
exposure of luminal components to the underlying tissue.stigative Pathology. Published by Elsevier IncA dysfunctional barrier combined with an aberrant immune
response are thought to be major risk factors for IBD.4
The protein networks enabling intestinal barrier function
are known as cell-cell junctions, which include the tight
junction and adherens junction. Cell-cell junctions can
confer strength or pore-forming abilities to the barrier.5. All rights reserved.
Soroosh et alA major transmembrane protein in the adherens junction is
E-cadherin, whereas tight junction transmembrane proteins
include the junctional adhesion molecule family and claudin
family of proteins.5 These transmembrane proteins are
connected to cytosolic adaptor proteins, which include the
zona occludens protein family and cingulin, which, in turn,
connect to the actin cytoskeleton of the cell.6 This connec-
tion between cells to the underlying cellular cytoskeleton
confers rigidity and strength to the junction.7 However,
junctional complexes are also highly dynamic.8 To remove
damaged proteins, these complexes are continually inter-
nalized and recycled back to the membrane or degraded.9 To
replace degraded proteins, junctional proteins are constantly
synthesized by intestinal epithelial cells. When any of these
aspects of the junctional dynamics are dysregulated, barrier
dysfunction is likely to occur.
One of the pathways the intestinal epithelium uses to
regulate the levels of tight junction proteins is by using
miRNAs.10 miRNAs are small noncoding RNAs that
repress gene expression by binding to complementary se-
quences on mRNAs. Multiple studies have assayed alter-
ations in miRNAs in IBD patients using unbiased
methods.11 A subset of these miRNAs, including miR-223
and miR-301a, regulate intestinal epithelial barrier func-
tion.12,13 One miRNA consistently shown to be elevated in
IBD patients is miR-24, yet the possible role for miR-24 in
IBD is unclear. Two studies have demonstrated 2- and 17-
fold changes in miR-24 in colonic biopsies from actively
inﬂamed UC patients compared with controls.14,15 In addi-
tion, two studies have observed a twofold increase in blood-
associated miR-24 in UC active patients compared with
controls.16,17 In the results presented herein, using semi-
quantitative real-time PCR, miR-24 levels were found to be
elevated in biopsies and whole blood from UC actively
inﬂamed patients. To better deﬁne a possible role for miR-
24 in the pathogenesis IBD, it was determined that miR-
24 was expressed by intestinal epithelial cells in UC
patients. When overexpressed in vitro, intestinal barriers in
target epithelial cells failed to establish. Although cells
overexpressing miR-24 grew normally, the protein levels of
the tight junction adaptor protein cingulin were signiﬁcantly
reduced. When cingulin was down-regulated in intestinal
epithelial cells, barrier formation was impaired. Therefore,
targeting the miR-24ecingulin axis may represent one
pathway to strengthen the intestinal barrier and reduce
inﬂammation in UC patients.
Materials and Methods
Clinical Samples
Colonic tissue biopsies and blood used in the miRNA
analyses were obtained from the University of California
Los Angeles Center for Inﬂammatory Bowel Diseases and
the G Oppenheimer Center for Neurobiology of Stress and
Resilience under the following institutional review1764boardeapproved protocols: numbers 12-00420, 13-000537,
and 11-000199. Colon tissue biopsies from patients who
met diagnostic Rome III criteria18 for IBS and healthy
control subjects were obtained during ﬂexible sigmoidos-
copy (at 30 cm) after tap water enemas. Colonic tissue used
for the mild and severe inﬂammation, on the basis of pa-
thology report analysis, was obtained from the University of
California Los Angeles Center for Inﬂammatory Bowel
Diseases under institutional review boardeapproved proto-
col 18-000209. Specimens were ﬂash frozen in liquid
nitrogen, and RNA was extracted with TRIzol reagent
(Thermo Fisher Scientiﬁc, Waltham, MA). A Ficoll gradient
(Roche, Basel, Switzerland) was used to isolate peripheral
blood mononuclear cells from whole blood, according to the
manufacturer’s instructions. All University of California
Los Angeles samples were obtained after a written informed
consent was provided. Human UC patient colonic tissue
used for the microarray analysis was obtained from Origene
(Rockville, MD). Diagnoses were conﬁrmed by an inde-
pendent set of pathologists associated with Origene.
Microarray Origene samples were analyzed, as previously
described.19 Samples were obtained through institutional
review board protocols and with documented patient con-
sent, all from accredited US-based medical institutions. The
microarray data are accessible through the Gene Expression
Omnibus (https://www.ncbi.nlm.nih.gov/geo; accession
number GSE77013).
Cell Culture
Caco-2 and T84 cells (ATCC, Manassas, VA) were grown
at 37C with 5% CO2. The cells were grown in Dulbecco’s
modiﬁed Eagle’s medium (Corning, Corning, NY) supple-
mented with 10% fetal bovine serum (Sigma, St. Louis,
MO) and 1% penicillin-streptomycin (Corning). To sub-
culture cells, conﬂuent monolayers were washed with
phosphate-buffered saline (PBS) and incubated with 0.25%
trypsin with 1 mmol/L EDTA (Thermo Fisher Scientiﬁc).
Suspended cells were centrifuged at 233  g for 5 minutes.
Both Caco-2 and T84 cells were split at a 1:5 ratio.
Barrier Assays
Transepithelial electrical resistance (TEER) was used as a
measurement of barrier integrity. A total of 100,000 cells
were plated on 6.5-mm transwell inserts that had 0.4-mm
pores (Thermo Fisher Scientiﬁc). A TC20 Automated cell
counter was used to determine cell numbers (Bio-Rad
Laboratories, Hercules, CA). Each subsequent day, TEER
was measured using a dual electrode connected to an
epithelial volt/ohm meter (World Precision Instruments,
Sarasota, FL). On the last day of the experiment, dextran
ﬂux was measured. A solution containing 50 mg ﬂuorescein
isothiocyanateelabeled 4-kDa dextran and 50 mg of Alex-
aFluor 555elabeled 10-kDa dextran (Thermo Fisher Sci-
entiﬁc), diluted in Hanks’ balanced salt solution, was usedajp.amjpathol.org - The American Journal of Pathology
miR-24 Regulates the Intestinal Barrier(Corning). The dextran solution (100 mL) was added to the
top of the transwell; and every 2 hours, for 6 total hours, 50
mL of the media in the bottom of the transwell was sampled.
A Synergy HT plate reader was used to measure ﬂuores-
cence (BioTek Instruments, Winooski, VT). To obtain ab-
solute amount of dextran ﬂux, a standard curve was used.
Transfections
Cells were transfected during plating, and all transfection
reactions were performed in Opti-MEM media (Gibco).
Seventy micromolar lipofectamine RNAiMax reagent was
used, according to the manufacturer (Invitrogen, Carlsbad,
CA). For overexpression experiments, both an miR-24 pre-
cursor and an miRNA precursor negative control were used
at the concentration of 50 nmol/L (PM10737 and AM17110,
respectively; Ambion, Austin, TX). For inhibition experi-
ments, a chemically modiﬁed20 miR-24 antisense oligonu-
cleotide and negative control were used at the concentration
of 50 nmol/L (YC10201383-FZA and YC10202119-FZA;
Qiagen, Hilden, Germany). For siRNA experiments, both the
cingulin siRNA and negative control were used at the con-
centration of 50 nmol/L (S33237 and 4390843, respectively;
Ambion). To produce miR-24 overexpression of 15-fold, 50
pmol/L control precursor and miR-24 precursors were used.
RNA Extraction, cDNA Synthesis, and Real-Time
Quantitative PCR
An miRNeasy kit (Qiagen) was used to extract and purify
mRNA and miRNA from tissue or cells grown on transwells,
according to the manufacturer’s instructions. To harvest,
transwell cells were ﬁrst washed twice with PBS and then the
membrane was excised. The membrane was then submerged
in Qiazol before storing lysed cells at 80C (Qiagen). All
other puriﬁcation steps were performed according to the
manufacturer’s instructions. To generate cDNA frommRNA,
an iScript cDNA synthesis kit was used (Bio-Rad Labora-
tories). mRNA (500 ng) was reverse transcribed into cDNA,
according to the manufacturer’s instructions. A miRCURY
LNA RT kit (Qiagen) was used to generate cDNA from 100
ng ofmiRNA, according to themanufacturer’s instructions. A
CFX384 real-time PCR system was used to amplify and
detect SYBR Greenemediated signal (Bio-Rad Labora-
tories). To measure miR-24, a miRCURYLNAmiRNA PCR
assay primer was used (YP00204260; Qiagen). The house-
keeping primers for miRNA experiments were U6 small nu-
clear RNA and 5S rRNA (YP00203907 and YP00203906,
respectively; Qiagen). Cingulin (CGN ), E-cadherin (CDH1),
and claudin-7 (CLDN7) primers were purchased from Inte-
grated DNA Technologies (Coralville, IA). b-Actin (ACTB)
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH )
were used as housekeeping genes for mRNA analysis. The
primer sequences are as follows: CGN, 50-GCAA-
CAAGGAGCTCCAGAAC-30 (forward) and 50-
CCCTGGACATGTTTCAGCTT-30 (reverse); CDH1, 50-The American Journal of Pathology - ajp.amjpathol.orgGGATTGCAAATTCCTGCCATTC-30 (forward) and
50-AACGTTGTCCCGGGTGTCA-30 (reverse); CLDN7,
50-GGATGATGAGCTGCAAAATG-30 (forward) and
50-CACCAGGGAGACCACCATTA-30 (reverse); ACTB, 50-
CCCAGCACAATGAAGATCAA-30 (forward) and 50-
ACATCTGCTGGAAGGTGGAC-30 (reverse); GAPDH, 50-
ATGTTCGTCATGGGTGTGAA-30 (forward) and 50-
GGTGCTAAGCAGTTGGTGGT-30 (reverse); PLEKHA7,
50-TAAAGACAGCCGAGAAGAAG-30 (forward) and 50-
TGTCGGCACTGAAGTAGTAG-30 (reverse); CLDN2, 50-
TGGCCTCTCTTGGCCTCCAACTTGT-30 (forward) and
50-TTGACCAGGCCTTGGAGAGCTC-30 (reverse);
CLDN3, 50-CATCACGTCGCAGAACATCT-30 (forward)
and 50-AGCAGCGAGTCGTACACCTT-30 (reverse); and
KRT8, 50-CGAGGATATTGCCAACCGCAG-30 (forward)
and 50-CCTCAATCTCAGCCTGGAGCC-30 (reverse). The
comparative Ct method was used to calculate fold change
relative to the housekeeping genes.21
Western Blot Analysis
Conﬂuent monolayers were washed twice with PBS and then
themembrane was excised.Membranes were then submerged
in 1Lammeli sample buffer (Bioland Scientiﬁc, Paramount,
CA) supplemented with 10% 2-mercaptoethanol (Sigma).
Samples were left on ice for 30 minutes before slowly passing
lysates through a 25-gauge needle. Lysates were then incu-
bated at 95C for 5 minutes, and then 10 mL of each sample
was added to a 4% to 20% SDSecontaining polyacrylamide
gel (Bio-Rad Laboratories). A Trans-Blot Turbo system (Bio-
Rad Laboratories) was used to transfer proteins onto a poly-
vinylidene diﬂuoride membrane. Membranes were then
blocked for 1 hour at room temperature in 5% milk in PBS
with 0.01% Tween-20. Membranes were then incubated with
primary antibody diluted in 5% bovine serum albumin over-
night at 4C. After ﬁve 10-minute washes with PBS with
0.01% Tween-20, the membrane was then incubated in sec-
ondary antibody diluted in 5% milk in PBS with 0.01%
Tween-20 for 1 hour at room temperature. After ﬁve 10-
minute washes with PBS with 0.01% Tween-20, protein was
visualized using a Clarity enhanced chemiluminescence kit
(Bio-Rad Laboratories) and ChemiDoc Touch Imager (Bio-
Rad Laboratories). The cingulin (117796) and claudin-2
(53032) antibodies were from Abcam (Cambridge, UK).
The claudin-7 (349100) and E-cadherin (clone 4A2C7) anti-
bodies were from Invitrogen. The claudin-3 (SAB4500435)
and PLEKHA7 (HPA038610) antibodies were from Sigma-
Aldrich (St. Louis, MO). The GAPDH antibodywas fromCell
Signaling Technologies (Danvers, MA; clone 14C10).
Horseradish peroxidaseeconjugated secondary antibodies
were obtained from Jackson Immunoresearch (WestGrove, PA).
Cell Growth and Apoptosis Assays
To measure cell growth, 50,000 cells were plated in 24-well
plates in duplicate. Each day after seeding, cells were1765
Figure 1 miR-24 is elevated in biopsies and blood from ulcerative
colitis patients. A: Real-time PCR was used to assess miR-24 levels in
colonic biopsies from healthy controls, actively inﬂamed ulcerative colitis
(UC) patients, noninﬂamed (inactive) UC patients, irritable bowel syndrome
(IBS) patients, or Crohn disease (CD) patients. B: Real-time quantitative
PCR measurements of miR-24 from human blood collected from patients
with active UC, CD, or healthy controls. C: In situ hybridization of miR-24 in
colon tissue from an actively inﬂamed UC patient or healthy control. Data
are expressed as means  SEM. n Z 26 (A, healthy controls); n Z 48
(A, actively inﬂamed UC patients); n Z 9 [A, noninﬂamed (inactive) UC
patients]; n Z 18 (A, IBS patients); n Z 22 (A, CD patients); n Z 8
(B, patients with active UC); n Z 6 (B, patients with active CD); n Z 7
(B, healthy controls). ***P < 0.001. Scale bars Z 50 mm (C).
Soroosh et altrypsinized and a TC20 Automated Cell Counter (Bio-Rad
Laboratories) was used to count the cells. To measure cell
proliferation, 10,000 cells were plated in 96-well plates and a
bromodeoxyuridine assay kit was performed according to the
manufacturer (Cell Signaling). To measure apoptosis, a Cas-
pase GLO 3/7 assay (Promega, Madison, WI) was used using
the manufacturer’s instructions. Brieﬂy, cells grown on
transwells were washed twice with PBS, and the membrane
was excised and submerged in the buffer provided by the kit.
After 15 minutes of incubation with shaking, a BioTek plate
reader was used to measure luminescence from 50 mL of
lysate. As a positive control, staurosporine (Tocris, Bristol,
UK) was added to the bottom of the transwell at a concen-
tration of 2 mmol/L for 8 hours before conducting the assay.
Lysis buffer was used to measure background luminescence.
As an alternate method to measure apoptosis, a Click-it ter-
minal deoxynucleotidyl transferase-mediated dUTP nick-end
labeling (TUNEL) kit (Invitrogen) was performed on cells at
the end point of TEER experiments, according to the manu-
facturer. DAPI (Invitrogen) was used as the nuclei stain.
Staurosporine was used as a positive control for TUNEL as-
says and was used at the concentration of 2 mmol/L for a total
of 3 hours for Caco-2 cells or 16 hours for T84 cells.
Immunoﬂuorescence
Cells grown on transwells were washed twice with PBS and
then ﬁxed in 100% cold methanol for 20 minutes at 20C.
After two subsequent washes with PBS, transwells were
blocked in 5%bovine serumalbumin inPBS for 1 hour at room
temperature. The transwell membraneswere then excised from
the transwell and incubated with mouse antiezona occludens
protein 1 (339100; Invitrogen) overnight at 4C in a humidiﬁed
container. Claudin-2, claudin-3, and claudin-7 antibodies were
the same as used forWestern blot analyses. The following day,
after three washes in PBS, the transwell was incubated with a
goat anti-mouse ﬂuorescently labeled 488 antibody for 1 hour
at room temperature (Invitrogen).After threewasheswithPBS,
nuclei were stained with DAPI for 1 minute (Invitrogen), and
ProlongGold (Invitrogen) was used tomountmembranes onto
slides. Slides were imaged using an upright microscope (Zeiss,
Oberkochen, Germany).
In Situ Hybridization
A double-DIG labeled miRCURY detection probe for
miR-24 (YD00617308-BCG; Qiagen) was used, as previ-
ously described.22
Statistical Analysis
Statistical differences between groups were evaluated using
an unpaired two-tailed t-test. Graphing was completed using
GraphPad Prism version 6 (GraphPad Software, Inc., San
Diego, CA). P < 0.05 was considered statistically
signiﬁcant.1766Results
miR-24 Is Elevated in Biopsies and Blood from
Ulcerative Colitis Patients
Multiple studies have seen that miR-24 is elevated in the
serum and colon of active inﬂamed ulcerative colitisajp.amjpathol.org - The American Journal of Pathology
Figure 2 miR-24 overexpression inhibits barrier formation. A: Real-time PCR was used to determine miR-24eoverexpressing Caco-2 and T84 cells after
transfection. B: Illustration showing two different methods to measure barrier function in vitro. C: Measurements of transepithelial electrical resistance (TEER)
over time in Caco-2 or T84 cells treated with a control miRNA or miR-24 miRNA. D and E: A 4-kDa (D) or a 10-kDa (E) dextran ﬂux in Caco-2 or T84 cells was
measured at the end point of the experiment. F: At the end point of the experiment, real-time quantitative PCR was used to measure miR-24 expression in
control miRNA inhibitoretreated cells or miR-24 inhibitoretreated cells. G: TEER was measured in control or miR-24 inhibitoretreated cells during barrier
establishment. Each graph is representative of three separate experiments with signiﬁcant results conducted in experimental triplicate. Data are expressed as
means  SD. *P < 0.05, **P < 0.01, and ***P < 0.001.
miR-24 Regulates the Intestinal Barrier(UC-active) patients.14e17 Although many studies have
analyzed the effects of miR-24 on oncogenesis, few
studies have proﬁled the function of miR-24 in the
context of IBD. To validate these microarrays and RNA-
sequencing studies, human colonic biopsies were ob-
tained from patients undergoing colonoscopy procedures
and real-time PCR was performed. Healthy controls were
compared with UC-active patients, UC-inactive patients,
IBS patients, and CD patients. It was observed that miR-
24 levels were elevated sevenfold in UC-active patients
(P < 0.0001) compared with the other groups, who had
similar levels of miR-24 (Figure 1A). In UC-active pa-
tients, the elevated levels of miR-24 do not appear to be
exclusive to colonic tissue as miR-24 was also elevated
fourfold in the blood of UC-active patients compared with
healthy controls and CD patients (Figure 1B). To deter-
mine the subset of cells that express miR-24, in situ hy-
bridization was performed on colonic sections from UC
patients and on healthy controls. It was observed
that miR-24 localized to intestinal epithelial crypts in
the colon (Figure 1C). These results indicate that in
UC patients, miR-24 is speciﬁcally elevated in the in-
testinal epithelium and this elevation persists in the
bloodstream.The American Journal of Pathology - ajp.amjpathol.orgmiR-24 Overexpression Signiﬁcantly Disrupts
Intestinal Barrier Function
Given the localization of miR-24 to the colonic epithelium,
which functions to generate a selectively permeable barrier
that lines the gut, the effects of miR-24 on barrier formation
were tested. If miR-24 regulates the barrier and miR-24 is
altered in IBD, this alteration could contribute to the path-
ogenesis of IBD. Two barrier-forming human cell lines of
intestinal epithelial origin were used, Caco-2 and T84 cells.
As miR-24 is elevated in UC-active patients (Figure 1, A
and B), an miR-24 mimic was transfected into Caco-2 and
T84 cells. A 40-fold increase or greater in miR-24 was
observed in both cell lines compared with control
mimicetreated cells (Figure 2A). After plating both control
or miR-24eoverexpressing cells in transwells, two methods
to test barrier function were then performed. As tight
junctions form a barrier against ion ﬂow, an electrode can be
used to measure TEER (Figure 2B). Another method to test
barrier function is a dextran ﬂux assay. In this assay, ﬂuo-
rescently labeled dextran is added to the upper chamber of
the transwell and the amount of dextran in the lower
chamber is measured bihourly (Figure 2B). On every
experiment performed, control cells gained TEER at an1767
Figure 3 miR-24 overexpression does not increase in-
testinal epithelial cell apoptosis. A: Caspase 3/7 activity, a
measurement of apoptosis, on control or miR-24etreated
Caco-2 or T84 cells at the end point of the transepithelial
electrical resistance experiment. B: A terminal deoxy-
nucleotidyl transferase-mediated dUTP nick-end labelling
(TUNEL) assay was used to determine the presence of cells
undergoing apoptosis after control miRNA or miR-24 miRNA
treatment. Staurosporine was used as a positive control for
apoptosis experiments. Each graph is representative of two
(T84) or three (Caco-2) separate experiments conducted in
experimental triplicate. Data are expressed as means  SD.
***P < 0.001. Scale bar Z 50 mm (B). HPF, high-power
ﬁeld.
Soroosh et alexponential rate. However, cells overexpressing miR-24 had
diminished TEER at all time points (Figure 2C). To test if
these alterations in barrier function occur at lower levels of
overexpression, oligonucleotides were diluted to obtain a
15-fold overexpression of miR-24. Overexpression was still
sufﬁcient to impair barrier function (Supplemental
Figure S1, A and B). For both T84 and Caco-2 cells,
miR-24 overexpression signiﬁcantly increased the amount
of 4- and 10-kDa dextran ﬂux at all time points (Figure 2, D
and E). In control Caco-2 cells, some dextran ﬂuxed over
time, whereas T84 cells were almost completely imperme-
able to dextran ﬂux when a high TEER was established
(Figure 2, D and E). These data suggest that miR-24 regu-
lates the formation of the intestinal epithelial barrier. To test
if miR-24 inhibition could accelerate barrier formation,
antisense miR-24 oligonucleotides were added to the cells
during barrier formation. Although antisense miR-241768oligonucleotides caused a dramatic decrease in miR-24 in
both Caco-2 and T84 cells, no alterations were observed in
the establishment of barrier function, as measured by TEER
(Figure 2, F and G).
miR-24 Overexpression Does Not Increase Intestinal
Epithelial Cell Apoptosis
To understand the potential mechanism for the disruption of
barrier function in cells with elevated miR-24, assays for
apoptosis were performed. It would be detrimental to the
establishment of a barrier if apoptosis is increased. As a ﬁrst
measurement of apoptosis, a caspase 3/7 activity assay was
performed on Caco-2 and T84 cells with altered TEERs.
Overexpression of miR-24 in Caco-2 cells reduced
apoptosis, as demonstrated by decreased caspase 3/7 activ-
ity. In T84 cells, no difference in caspase 3/7 activity wasajp.amjpathol.org - The American Journal of Pathology
Figure 4 miR-24 overexpression does not reduce intestinal epithelial
cell proliferation. A: A quantiﬁcation of Caco-2 or T84 cell numbers over the
period of 4 days after transfection with either a control miRNA or an miR-24
miRNA. B: To measure cell proliferation, cells were pulsed with bromo-
deoxyuridine (BrdU) for either 2 or 4 hours before measurement of BrdU
incorporation with anti-BrdU antibodies. Cells plated in the absence of
BrdU were used as a negative control. Each graph is representative of three
separate experiments conducted in experimental triplicate. Data are
expressed as means  SD.
miR-24 Regulates the Intestinal Barrierobserved between the two groups (Figure 3A). As a positive
control, cells were treated with staurosporine, which induces
apoptosis in caspase-independent and caspase-dependent
mechanisms,23 as demonstrated by a dramatic increase in
caspase 3/7 activity (Figure 3A). As an alternate method to
measure apoptosis, a TUNEL assay was performed on
transwell inserts from Caco-2 and T84 cells. Both control
miRNAe and miR-24 miRNAetreated cells displayed low
levels of TUNEL positivity that are indicative of a healthy
barrier (Figure 3B). Staurosporine treatment, similar to
increased caspase activity, markedly increased TUNEL
positivity (Figure 3B).miR-24 Overexpression Does Not Reduce Intestinal
Epithelial Cell Proliferation
If cells overexpressing miR-24 were not able to proliferate,
then the establishment of barrier would be hindered. To
measure cell proliferation, Caco-2 and T84 intestinal
epithelial cells were plated sparsely and counted over the
course of 4 days or were pulsed with bromodeoxyuridine.
It was observed that miR-24eoverexpressing cells had
similar growth trajectories as control cells over the period
of 4 days (Figure 4A). Both control miRNA and miR24
miRNA cells also had similar levels of bromodeoxyuridine
uptake at 2 hours, and these levels increased at 4 hours;
however, no differences were seen between the groups
(Figure 4B).The American Journal of Pathology - ajp.amjpathol.orgmiR-24 Overexpression Does Not Alter Junctional
Morphology
As apoptosis levels and proliferation rates were similar be-
tween control and miR-24 miRNAetreated cells, but barrier
function was hindered in miR-24eoverexpressing cells, it
was next sought to visualize the gross architecture of cell-
cell junctions. On the ﬁnal day of the transwell experiment,
cells were ﬁxed and junctions were labeled with ﬂuo-
rescently labeled antibodies. Similar to control cells, Caco-2
cells overexpressing miR-24 had intact tight junctions, as
observed by zona occludens protein 1, claudin-3, and
claudin-7 localization and levels (Figure 5). In T84 cells,
claudin-2 immunoﬂuorescence labeling was similar between
control and miR-24eoverexpressing cells (Supplemental
Figure S2). Thus, the effect of miR-24 negatively regu-
lating the intestinal barrier appears to occur through speciﬁc
barrier-promoting proteins.
miR-24 Regulates the mRNA and Protein Levels of the
Tight JunctioneAssociated Protein, Cingulin
As miR-24eoverexpressing cells grew normally and overall
junctional appearance seemed normal, Western blot ana-
lyses were performed on a panel of established junctional
proteins to determine how miR-24 regulates the intestinal
barrier. The transmembrane proteins claudin-2, claudin-3,
and claudin-7 were unaltered in both Caco-2 and T84 cells
overexpressing miR-24 compared with controls
(Figure 6A). Although the levels of the cell-cell adhesion
protein E-cadherin were unaltered in Caco-2 cells over-
expressing miR-24, in T84 cells overexpressing miR-24, a
30% loss in E-cadherin was observed compared with con-
trols (Figure 6A). However, the tight junctioneassociated
protein and known direct target of miR-24,24 cingulin,
was signiﬁcantly decreased: 60% to 70% in miR-
24eoverexpressing Caco-2 cells and 80% to 90% in T84
cells compared with controls (Figure 6A). The protein
levels of a binding partner of cingulin, pleckstrin homology
domain-containing family A member 7 (PLEKHA7),25
were not altered in miR-24eoverexpressing Caco-2 cells
compared with controls (Figure 6A). In T84 cells, PLE-
KHA7 protein levels were reduced signiﬁcantly by 20%. In
both cell lines, claudin-2, claudin-3, and claudin-7 protein
levels were not altered by miR-24 overexpression. To better
understand how miR-24 might regulate cingulin protein
levels, the mRNA levels in transfected cells were deter-
mined by real-time PCR. Similar to the protein levels,
cingulin mRNA was signiﬁcantly decreased in miR-
24eoverexpressing cells (Figure 6B). The mRNA levels of
PLEKHA7, claudin-2, claudin-3, and claudin-7 were not
altered by miR-24 overexpression, whereas the levels of E-
cadherin mRNA were signiﬁcantly decreased in Caco-2 and
T84 cells (Figure 6B). These results suggest that the effect
of miR-24 on the intestinal barrier could be due to effects
on cingulin mRNA.1769
Figure 5 miR-24 overexpression does not alter
junctional morphology. Caco-2 cells were ﬁxed at the
end point of the experiment, and junctions were
labeled with zona occludens protein 1 (ZO-1), claudin-
3 (Cldn-3), and claudin-7 (Cldn-7) antibodies. Nuclei
were labeled with a DNA dye. To control for non-
speciﬁc secondary antibody binding a control was
included that only contained the secondary antibody
(secondary control). Scale bar Z 25 mm.
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Down-Regulated in Ulcerative Colitis
To test if cingulin is necessary for the establishment of an
intestinal epithelial barrier, an siRNA was used to down-
regulate cingulin during barrier establishment in both
Caco-2 and T84 cells (Figure 7A). Of interest, cingulin
delayed the formation of an intestinal barrier as knock-
down of cingulin in both cell lines resulted in an atten-
uated TEER (Figure 7B). Dextran ﬂux was also altered in
these cells. Both the 4- and 10-kDa dextran assays
revealed increased paracellular permeability that almost
doubles over the course of the measurement (Figure 7, C
and D). Given the role of cingulin in barrier function and
the alteration of barrier function in IBD patients, a
compelling question is whether cingulin is altered in IBD
patients. Microarray analysis of human colonic biopsies
from patients with active UC and healthy controls
revealed a signiﬁcant 3.2-fold decrease in cingulin levels
in UC, even when normalized to an epithelial cell marker,
cytokeratin 8 (P Z 0.05) (Figure 7E). However, the
microarray analysis did not reveal a difference in cingulin
levels in CD compared with controls (data not shown).
Furthermore, cingulin expression was decreased in
severely inﬂamed UC patient colonic biopsies compared1770with mildly inﬂamed UC patient colonic biopsies
(Figure 7F). Therefore, miR-24emediated regulation of
cingulin is likely important for intestinal epithelial barrier
function, and this relationship is correlated with disease
severity in UC patients.Discussion
The intestinal epithelial barrier is vital for normal gut
homeostasis and the prevention of inﬂammation. IBD pa-
tients exhibit a faulty epithelial barrier.3 The establishment
and maintenance of the epithelial barrier is regulated in part
by miRNAs.26 Therefore, aberrant expression of miRNAs
may contribute to the pathogenesis of IBD. Multiple studies,
using unbiased methods, have identiﬁed miR-24 as being
elevated in the sera and colonic biopsies from IBD.14e17 In
this study, the gold standard for measuring miRNA
expression, real-time quantitative PCR, was used to not only
validate these large-scale studies but extend an under-
standing of colonic miR-24 expression in noninﬂamed UC,
IBD, and CD patients. miR-24 was speciﬁcally elevated in
colonic biopsies from actively inﬂamed UC patients and not
noninﬂamed UC, CD, or IBD patients compared with
healthy controls. As miR-24 localized to the colonicajp.amjpathol.org - The American Journal of Pathology
Figure 6 miR-24 regulates the mRNA and protein levels of the tight junctioneassociated protein cingulin. A: After treatment of Caco-2 cells with either a
control miRNA or an miR-24 miRNA, Western blot analyses were performed against cingulin, claudin-2 (Cldn-2), claudin-3 (Cldn-3), claudin-7 (Cldn-7),
PLEKHA7, and E-cadherin. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the loading control. Each graph is representative of three
separate experiments conducted in experimental triplicate. B: Real-time PCR was used to quantify Cgn, Cldn2, Cldn3, Cldn7, PLEKHA7, and E-cadherin mRNA
levels in control miRNAe or miR-24 miRNAetreated Caco-2 cells. Three independent experiments were performed (A). Data are expressed as means  SD (A);
data are expressed as means  SEM (B). *P < 0.05, **P < 0.01, and ***P < 0.001.
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Figure 7 Cingulin is decreased in ulcerative colitis (UC) patients, and
down-regulation of cingulin impairs barrier formation. A: Real-time quan-
titative PCR was used to measure cingulin expression in Caco-2 and T84
cells in control or cingulin siRNAetreated cells. Results are representative
of three independent experiments. BeD: Transepithelial electrical resis-
tance (TEER; B) or dextran ﬂux (C and D) was measured over time in cin-
gulin siRNAetreated Caco-2 and T84 cells. Results are representative of
three independent experiments. E: Cingulin mRNA levels in healthy controls
or UC-active patients, as determined by microarray analysis. To adjust for
differences in epithelium, cingulin levels were normalized to cytokeratin 8
(Krt8). F: Real-time PCR measurement of cingulin in either mildly inﬂamed
or severely inﬂamed UC patients. Data are expressed as means  SEM
(AeD). n Z 7 (E, healthy controls, and F, mildly inﬂamed UC patients);
n Z 8 (E, UC-active patients); n Z 4 (F, severely inﬂamed UC patients).
*P < 0.05, **P < 0.01, and ***P < 0.001.
Soroosh et alepithelium, the alteration of miR-24 levels in UC appears to
be speciﬁc to intestinal epithelial cells. The cause for
up-regulation of miR-24 in the colon remains unknown as
intestinal epithelial cells treated with cytokines or bacterial
antigens failed to show an up-regulation in miR-24 levels
(data not shown).
Although there is a multitude of evidence for miR-24
alterations in UC patients, information was lacking about1772the function for miR-24 in intestinal epithelial cells. As a
major function of intestinal epithelial cells is to establish a
barrier, the role for miR-24 in barrier function was tested
and miR-24 was found to have a signiﬁcant detrimental
effect. The intestinal epithelial barrier is a combination of
cell growth, death, and junctional dynamics. This study
observed that miR-24 overexpression did not alter cell
growth, death, or overall junctional architecture. To under-
stand how miR-24 might regulate barrier function even with
seemingly normal tight junction architecture, the levels or
localization of individual junctional proteins that have been
previously shown to be directly or indirectly regulated by
miR-24 was assessed.24,27 Although overexpression did not
affect zona occludens protein 1 localization or E-cadherin
protein levels, miR-24 overexpression in intestinal epithelial
cells resulted in a striking loss of cingulin protein expres-
sion. miR-24 regulates cingulin through a single binding site
on the 30 untranslated region of cingulin.24 Cingulin is a
globular protein located in the cytoplasm that can interact
with many components of the adherens and tight junc-
tions.28 A previous study tested if cingulin participated in
barrier function; however, those experiments were per-
formed on renal epithelial cells.29 Therefore, it was tested if
cingulin regulates intestinal barrier function, and it was
determined that cingulin participates in the formation of a
tight barrier.
Although miR-24 inhibits apoptosis, it remains unclear
how it regulates apoptosis in intestinal epithelial cells. It has
previously been reported in heart, liver, and bladder
epithelial cells that miR-24 overexpression also reduces
apoptosis.30e32 The mechanisms for miR-24 regulating
apoptosis have been proposed to be direct regulation of Bim
and caspase 3/8. Further experimentation testing these
known targets of miR-24 in intestinal epithelial cells also
represents important questions to be addressed in future
studies. As the lack of increased apoptosis was evident
when miR-24 was altered, it was clear that miR-24 regulated
cell-cell junctions. Previous evidence indicates that TEER
measures a pore pathway, whereas dextran ﬂux measures a
leak pathway33; and it has been shown that there can be
alterations to the pore pathway without alterations to the
leak pathway.34 In this study, it was observed that miR-24
and cingulin both regulated TEER formation and dextran
ﬂux, suggesting that miR-24 and cingulin are important
players in intestinal barrier function. Although these ob-
servations are novel for miR-24, cingulin has been linked to
both the pore and leak pathways. The pore pathway is
established by the binding of the claudin family of proteins
between cells and depends on the composition of tight and
leaky claudins.8 The leak pathway occurs when the pe-
ripheral actomyosin ring contracts, and this contraction is in
part regulated by the small GTPase RhoA. Cingulin has
been shown to negatively regulate RhoA and a leaky clau-
din, claudin-2.29,35 However, it was observed that increased
claudin-2 occurred in the kidney/duodenum and not the
ileum or colon of cingulin knockout mice.36 In this study,ajp.amjpathol.org - The American Journal of Pathology
miR-24 Regulates the Intestinal Barrieralthough miR-24 overexpression resulted in a drastic loss of
cingulin, there were no alterations in claudin-2 mRNA or
protein levels. Further studies on downstream targets for
miR-24 and cingulin should include an in-depth character-
ization of the localization and levels of claudins expressed
as well as the role for actomyosin contraction in intestinal
epithelial cells.
The elevation of miR-24 levels in both the colon and
blood could be a mechanism to open cell-cell junctions,
allowing for transmigration of immune cells to sites of
inﬂammation or infection. The increased levels of miR-24 in
UC patients appear to be secondary to inﬂammation as UC
patients in remission do not display this increase and genetic
alterations in miR-24 have not been observed in UC pa-
tients.37 Regardless of the cause for miR-24 up-regulation,
the data presented in this article suggest that reducing miR-
24 levels in actively inﬂamed UC patients could strengthen
the intestinal barrier. This strategy could be used to prevent
the vicious cycle of immune cell hyperactivation and further
barrier breakdown.
Through this work, strong evidence has been provided
that a speciﬁc miRNA, miR-24, is related to a speciﬁc issue
in IBD, intestinal barrier dysfunction. miRNAs have been
widely studied in IBD, with implications for biomarkers,
pathogenesis, and therapeutics. In this study, a role for miR-
24 in barrier integrity was established, which lays the
foundation for a variety of future studies investigating miR-
24 not only in IBD, but also in other barrier-associated
diseases.38 Mechanistically, it was established that in
colonic epithelial cells, cingulin is a target for miR-24 and
this interaction could be involved in the pathogenesis of UC.
Future directions will involve various animal models of
colitis and barrier dysfunction, using an miR-24 inhibitor or
miR-24 knockout mice to attempt to improve disease
outcome.
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